alfin inc said has received regulatory letter from office compliance food and drug administration asserting because labelling and certain advertising claims its glycel products new drugs within meaning federal food drug and cosmetic act for which approval has been obtained and misbranded labelling company said understands this action part industry wide investigation company added reviewing matter with counsel intends respond and corrective action necessary reuter 